Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort

Development of immunogens that elicit an anti-HIV-1 broadly neutralizing antibody (bnAb) response will be a key step in the development of an effective HIV-1 vaccine. Although HIV-1 bnAb epitopes have been identified and mechanisms of action studied, current HIV-1 envelope-based immunogens do not el...

Descripción completa

Detalles Bibliográficos
Autores principales: Granger, Luke A., Huettner, Isabella, Debeljak, Franka, Kaleebu, Pontiano, Schechter, Mauro, Tambussi, Giuseppe, Weber, Jonathan, Miro, Jose M., Phillips, Rodney, Babiker, Abdel, Cooper, David A., Fisher, Martin, Ramjee, Gita, Fidler, Sarah, Frater, John, Fox, Julie, Doores, Katie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505148/
https://www.ncbi.nlm.nih.gov/pubmed/34127581
http://dx.doi.org/10.1097/QAD.0000000000002988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505148/
https://www.ncbi.nlm.nih.gov/pubmed/34127581
http://dx.doi.org/10.1097/QAD.0000000000002988

Ejemplares similares